MCL1 and lymphoma: Whilst performing CRISPR/Cas9 whole genome knockout (KO) screens to identify factors that confer resistance to MCL-1-targeting BH3-mimetics in Eμ-Myc lymphoma cells, we additionally identified loss of the apoptotic effector BAX as a top hit [24].